Last reviewed · How we verify
Aspirin and Clopidogrel
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.
Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Prevention of stent thrombosis after percutaneous coronary intervention.
At a glance
| Generic name | Aspirin and Clopidogrel |
|---|---|
| Also known as | Aspirin: acid acetylsalycilic, Clopidogrel: plavix, Aspirin Enteric Coated Tablets ,Bayer HealthCare AG ;, Plavix, Aspirin Enteric Coated Tablets |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antiplatelet agent (dual therapy) |
| Target | Cyclooxygenase (COX) and P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), reducing thromboxane A2 production and platelet activation. Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-mediated platelet aggregation. Combined, they provide dual antiplatelet therapy with complementary mechanisms to reduce thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Prevention of stent thrombosis after percutaneous coronary intervention
Common side effects
- Bleeding
- Gastrointestinal bleeding
- Dyspepsia
- Bruising
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) (NA)
- Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin and Clopidogrel CI brief — competitive landscape report
- Aspirin and Clopidogrel updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI